CJC-1295 vs Ipamorelin: A Complete Research Comparison

These materials are research-grade reference compounds sold for laboratory research use only. They are not for human or veterinary use. 

CJC-1295 and ipamorelin are the classic co-studied pair in growth-hormone-axis research. They are examined together so often because they represent the two different secretagogue classes and engage two different receptors, which makes them complementary tools rather than alternatives. Understanding why they pair well starts with understanding why they are not the same kind of molecule.

This article compares them in depth and strictly in research terms: identity and structure, the two receptor systems, what the literature reports in animal and cell models, and how each is verified and handled. Every finding is framed within its experimental context, and nothing here is guidance for human or veterinary use.

At a Glance

• CJC-1295 is a modified analog of growth-hormone-releasing hormone (GHRH), studied at the GHRH receptor.
• Ipamorelin is a synthetic pentapeptide studied at the ghrelin receptor (GHS-R1a).
• They belong to complementary secretagogue classes: a GHRH analog and a GHRP.
• The pairing is common in research because the two classes engage different receptors.
• Both are research chemicals for laboratory use only, verified per lot by HPLC and mass spectrometry.

Quick Comparison

Attribute	CJC-1295	Ipamorelin
Peptide class	GHRH analog	Growth-hormone-releasing peptide (GHRP)
Receptor studied	GHRH receptor	Ghrelin receptor (GHS-R1a)
Structure	Modified GHRH(1-29) analog	Synthetic pentapeptide (5 residues)
Basis	Endogenous releasing hormone	Fully designed molecule
Noted feature	Engineered stability; DAC version for extended half-life	Selectivity in original characterization
Verification	HPLC + mass spectrometry, per-lot COA	HPLC + mass spectrometry, per-lot COA

What CJC-1295 Is?

CJC-1295 is a modified GHRH(1-29) analog carrying substitutions intended to improve stability relative to the unmodified fragment. A version incorporating a drug-affinity complex (DAC) is described as binding serum albumin, which is associated with a substantially extended circulating half-life in research settings (Teichman et al., 2006). It is studied at the GHRH receptor as an engineered representative of the GHRH sequence. Exact molecular weight and purity for any lot are documented on the Certificate of Analysis.

What Ipamorelin Is?

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) from the growth-hormone-releasing peptide class, characterized in its founding report as the first selective growth-hormone secretagogue (Raun et al., 1998). It acts at the ghrelin receptor, the same receptor engaged by endogenous ghrelin. Its non-natural residues are design features studied for their effect on receptor interaction and stability.

Two Complementary Receptor Systems

The reason this pair is studied together is that CJC-1295 acts at the GHRH receptor and ipamorelin acts at the ghrelin/growth-hormone-secretagogue receptor, GHS-R1a. These are two distinct receptor systems within the growth-hormone axis. The GHRP series, of which ipamorelin is a refined member, was historically central to the discovery of the ghrelin receptor and its ligand (Bowers, 2012; Kojima et al., 1999). Pairing a GHRH analog with a GHRP lets researchers examine both receptor arms in a single design.

What the Research Literature Reports?

Ipamorelin

Its founding report described selective secretagogue activity in animal models (Raun et al., 1998), and the broader ghrelin-receptor literature provides the pharmacological framework for the class (Bowers, 2012). Research focuses on receptor binding, downstream signaling, and selectivity.

CJC-1295

CJC-1295 is studied as a stabilized GHRH analog, with the DAC version investigated for prolonged exposure through albumin binding (Teichman et al., 2006). Research interest centers on how the modifications change exposure relative to the unmodified GHRH sequence. As with ipamorelin, these are mechanistic and model-level observations, not statements about human outcomes.

Structure, Stability, and Research Handling

CJC-1295 is a modified 29-residue GHRH analog; ipamorelin is a five-residue designed peptide. The size and design differences carry into their handling and stability considerations. General peptide-stability principles apply to both, and lot-specific stability is documented on the Certificate of Analysis rather than as a blanket duration.

How Researchers Choose Between Them?

Because they act on different receptors, the decision follows which arm of the growth-hormone axis a study targets, or whether the study is designed to engage both. Receptor target, stability profile, selectivity, and the depth of prior literature for the model of interest all factor in. Their complementary mechanisms are exactly why they are frequently studied as a pair.

Chemical Identity and Verification

Both are verified by mass spectrometry for identity and HPLC for purity, with results on a lot-specific Certificate of Analysis. Net peptide content is distinct from chromatographic purity. Reconcile every molecular figure against the COA before use.

Storage and Handling in a Laboratory Context

Store sealed material cold, shield it from light, and avoid repeated freeze-thaw. Lyophilized material is generally more stable than material in solution. Lot-specific stability is documented on the COA.

Research Limitations and Open Questions

The secretagogue literature rests largely on animal and cell models, and findings there do not translate directly to any human context. The distinction between the modified CJC-1295 analog and its DAC version matters and is sometimes blurred in secondary sources, so confirm which form a study or product refers to.

Frequently Asked Questions

What is the difference between CJC-1295 and ipamorelin?

CJC-1295 is a GHRH-receptor analog; ipamorelin is a ghrelin-receptor (GHS-R1a) agonist. They act on different receptors, which is why they are complementary.

Why are they studied as a pair?

Because they represent the two secretagogue classes and engage two different receptors, allowing both arms of the growth-hormone axis to be examined together.

How do their structures compare?

Ipamorelin is a five-residue synthetic peptide; CJC-1295 is a modified 29-residue GHRH analog.

What does the DAC version of CJC-1295 change?

It adds an albumin-binding complex associated with extended circulating half-life in research settings (Teichman et al., 2006).

Why is ipamorelin called selective?

Its original characterization reported a comparatively narrow secretagogue response in the models tested (Raun et al., 1998).

How is each verified for identity and purity?

By mass spectrometry for identity and HPLC for purity, documented on a lot-specific Certificate of Analysis.

Do these findings apply to people?

No. All cited work is in animal or cell models and describes mechanism and research outcomes only.

Related Reading

• CJC-1295 reference page
• Ipamorelin reference page
• Growth-Hormone Secretagogue Research Peptides (class overview)
• Lab Reports

References

1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID 9849822.
2. Teichman SL, et al. Prolonged stimulation of growth hormone by CJC-1295. J Clin Endocrinol Metab. 2006. PMID 16352683.
3. Bowers CY. History to the discovery of ghrelin. Methods Enzymol. 2012. PMID 22975043.
4. Kojima M, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999. PMID 10604470.

Research-use notice: CJC-1295 and ipamorelin are research chemicals sold for laboratory research use only. They are not for human or veterinary use. Every finding is reported in the specific research context of the cited study.